Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2019 06:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland

ZURICH, Switzerland and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
February 19, 2019 08:06 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Issues a Statement to Patients and Shareholders

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
February 04, 2019 08:22 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium

NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
January 25, 2019 07:15 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida

NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
January 22, 2019 08:40 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Granted Additional Patent for NurOwn® in Israel

NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative...
January 11, 2019 00:05 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA

NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
January 03, 2019 06:04 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week

NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that...
December 27, 2018 07:35 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Issues 2018 Letter to Shareholders

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a...
December 26, 2018 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial

NEW YORK and BOSTON, Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced...
December 17, 2018 07:34 ET | Source: BrainStorm Cell Therapeutics Inc.

FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis

NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...